Rabeprazole is an anti ulcer drug in the class of proton pump inhibitors (PPI); Rabeprazole is a PPI that suppresses gastric acid secretion by inhibiting the gastric H+K+ ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. Onset of action is 1 hour. Duration 24 hours. Oral bio availability is about 52% and peak plasma concentrations are reached about 3.5 hr after oral admin. The median inhibitory effect of rabeprazole on 24 hour gastric acidity is 88% of maximal after the first dose.

Rabeprazole is an anti ulcer drug in the class of proton pump inhibitors (PPI); Rabeprazole is a PPI that suppresses gastric acid secretion by inhibiting the gastric H+K+ ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. Onset of action is 1 hour. Duration 24 hours. Oral bio availability is about 52% and peak plasma concentrations are reached about 3.5 hr after oral admin. The median inhibitory effect of rabeprazole on 24 hour gastric acidity is 88% of maximal after the first dose.